Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Boehringer Ingelheim has acquired an investigational drug to treat nonalcoholic steatohepatitis, a liver disease, from Australia’s Pharmaxis. The drug, PXS4728A, is a semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 inhibitor that works by blocking leukocyte adhesion and tissue infiltration in inflammatory processes. Boehringer Ingelheim will pay about $30 million up front, and Pharmaxis will be eligible to receive development and commercialization milestone payments.
This article has been sent to the following recipient: